Media ReleasesSUDA Pharmaceuticals

View All SUDA Pharmaceuticals News


SUDA Pharmaceuticals - Investor Webinar


SUDA Pharmaceuticals Ltd (ASX: SUD) is pleased to invite shareholders and interested parties to an investor webinar and Q&A hosted by CEO & Managing Director Dr Michael Baker.

The webinar will focus on today’s announcement regarding SUDA’s global licensing agreement with Imperial College London for a novel invariant Natural Killer T (iNKT) cell therapy platform. Dr Baker will be joined on the webinar by Professor Anastasios Karadimitris.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.